Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months
TA Glauser, A Cnaan, S Shinnar, DG Hirtz… - …, 2013 - Wiley Online Library
Purpose: Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double‐blind therapy. Methods …
childhood absence epilepsy (CAE) based on 12 months of double‐blind therapy. Methods …
[引用][C] Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months
T Glauser, A Cnaan, S Shinnar, DG Hirtz… - …, 2013 - hsrc.himmelfarb.gwu.edu
"Ethosuximide, valproic acid, and lamotrigine in childhood absence epil" by Tracy Glauser,
Avital Cnaan et al. Home Search Browse Collections My Account About DC Network Digital …
Avital Cnaan et al. Home Search Browse Collections My Account About DC Network Digital …
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.
TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos… - Epilepsia, 2012 - europepmc.org
Purpose Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months
TA Glauser, A Cnaan, S Shinnar, DG Hirtz… - …, 2013 - einstein.elsevierpure.com
Purpose: Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods: A …
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods: A …
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months
TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos… - 2013 - pubmed.ncbi.nlm.nih.gov
Purpose Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months
TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos… - Epilepsia, 2013 - infona.pl
Purpose: Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double‐blind therapy. Methods …
childhood absence epilepsy (CAE) based on 12 months of double‐blind therapy. Methods …
[HTML][HTML] Ethosuximide, Valproic Acid and Lamotrigine in Childhood Absence Epilepsy: Initial Monotherapy Outcomes at 12 months
TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos… - Epilepsia, 2013 - ncbi.nlm.nih.gov
Purpose Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy based on 12 months of double blind therapy. Methods A double …
childhood absence epilepsy based on 12 months of double blind therapy. Methods A double …
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.
TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos… - Epilepsia, 2012 - europepmc.org
Purpose Determine the optimal initial monotherapy for children with newly diagnosed
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …
childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. Methods A …